Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cardiac Sarcoidos Multi-Center Prospective Cohort (CHASM-CS)

30 oktober 2026 uppdaterad av: Ottawa Heart Institute Research Corporation

Cardiac Sarcoidosis Multi-Center Prospective Cohort Study

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

Studietyp

Observationell

Inskrivning (Beräknad)

1500

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Sapporo, Japan, 060-8638
        • Rekrytering
        • Hokkaido University
        • Kontakt:
        • Huvudutredare:
          • Ichizo Tsujino, MD
    • Alberta
      • Calgary, Alberta, Kanada, T2N 2T9
        • Rekrytering
        • Libin Cardiovascular Institute of Alberta
        • Huvudutredare:
          • Russell Quinn, MD
        • Kontakt:
          • Russell Quinn, MD
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Rekrytering
        • University of Alberta Hospital
        • Kontakt:
          • Tomascz Hruczkowski, MD
        • Huvudutredare:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Rekrytering
        • St. Paul's Hospital
        • Kontakt:
          • Shanta Chakrabarti, MD
        • Huvudutredare:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 3A7
        • Rekrytering
        • QEII Health Sciences Center
        • Huvudutredare:
          • Ciorsti MacIntyre, MD
        • Kontakt:
          • Kim Anderson, MD
    • Ontario
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Rekrytering
        • Hamilton Health Sciences Centre
        • Huvudutredare:
          • Jeff Healey, MD
        • Kontakt:
          • Gerard Cox, MD
        • Kontakt:
          • Jeff Healey, MD
      • London, Ontario, Kanada, N6A 5A5
        • Rekrytering
        • London Health Sciences Centre
        • Kontakt:
          • Lorne Gula, MD
        • Huvudutredare:
          • Lorne Gula, MD
      • Newmarket, Ontario, Kanada, L3Y 2P9
        • Rekrytering
        • Southlake Regional Health Centre
        • Kontakt:
          • Bernice Tsang, MD
        • Huvudutredare:
          • Bernice Tsang, MD
      • Ottawa, Ontario, Kanada, K1Y 4W7
        • Rekrytering
        • University of Ottawa Heart Institute
        • Kontakt:
        • Huvudutredare:
          • David Birnie, MD
        • Kontakt:
      • Toronto, Ontario, Kanada, M5G 2C4
        • Rekrytering
        • Toronto General Hospital
        • Kontakt:
          • Andrew Ha, MD
        • Huvudutredare:
          • Andrew Ha, MD
    • Quebec
      • Montreal, Quebec, Kanada, H1T 1C8
        • Rekrytering
        • Montreal Heart Institute
        • Kontakt:
          • Lena Rivard, MD
        • Huvudutredare:
          • Lena Rivard, MD
      • Montreal, Quebec, Kanada, H3G 1A4
        • Rekrytering
        • McGill University Health Centre
        • Kontakt:
          • Fiorella Rafti
        • Huvudutredare:
          • Martin L Bernier, MD
      • Montreal, Quebec, Kanada, H2W 1T8
        • Har inte rekryterat ännu
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • Kontakt:
          • Julie Fleury, RN
        • Huvudutredare:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4P 0W5
        • Rekrytering
        • Prairie Vascular Research Inc-Regina General Hospital
        • Kontakt:
        • Huvudutredare:
          • Andrea Lavoie, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 99 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Electrophysiology Service patients

Beskrivning

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Primary Outcome for ALL Patients
Tidsram: Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Secondary Outcomes for ALL Patients
Tidsram: Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
Tidsram: Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tidsram: Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Tidsram: Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Huvudutredare: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
  • Huvudutredare: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
  • Huvudutredare: David Birnie, MD, Ottawa Heart Institute Research Corporation

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 augusti 2012

Primärt slutförande (Beräknad)

1 mars 2027

Avslutad studie (Beräknad)

1 december 2035

Studieregistreringsdatum

Först inskickad

10 november 2011

Först inskickad som uppfyllde QC-kriterierna

18 november 2011

Första postat (Beräknad)

22 november 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • UOHI-04

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .